Jaguar Health's news flow in 2026 tells you where the pressure is, and it is not on the science. In June the company began a review of strategic alternatives for crofelemer, its plant-based lead compound, and initiated a process to explore options. Around that review sits a dense sequence of capital moves: a June financing of 240 shares of Series P preferred stock for $2 million, a committed $40 million equity line of credit, a January licensing deal with an affiliate of Future Pak that brought $16 million of non-dilutive capital, and a further $3 million payment after Jaguar terminated a buy-back provision. In July, its Napo subsidiary signed a new manufacturing and supply agreement with Alivus Life Sciences for crofelemer.
A strategic review is management-speak for exploring a sale, a partnership, or a restructuring, and companies usually launch one when the status quo is not sustainable. For a company whose capital structure has long been the defining feature, that is the signal that matters more than any single financing.
- June: strategic review. Jaguar began exploring strategic alternatives for the crofelemer franchise.
- Financing stack. A $2M Series P preferred raise plus a committed $40M equity line of credit.
- Non-dilutive offsets. A January Future Pak licensing deal brought $16M, plus a later $3M payment.
Why the rating is Bearish
The reason to stay skeptical is structural. Crofelemer is a real, approved product with a genuine market, and the Future Pak licensing brought welcome non-dilutive cash. But a company that leans on a preferred raise and a $40 million equity line of credit, and then puts its lead asset under strategic review, is telling you the operating business does not fund itself and that the equity is the pressure-release valve. Equity lines and preferred instruments are dilutive by design, and a strategic review can end in a value-creating deal or in a distressed one. The base case for a name with this capital profile is caution.
The other side
The bull case is that the strategic review surfaces a buyer or partner who values crofelemer's franchise at more than the market gives Jaguar credit for, that the non-dilutive licensing capital buys time, and that a focused, well-capitalized owner could do more with the asset. That outcome is possible. But it is a bet on a favorable transaction closing, not on the underlying business, and until such a deal is announced, the dilution and financing risk dominate.
- Strategic review signals pressure. Companies explore alternatives when the status quo is unsustainable.
- Dilutive financing reliance. A preferred raise and a $40M equity line of credit are ongoing dilution.
- Real, approved product. Crofelemer has a market, and licensing brought non-dilutive capital.
- Binary outcome. A review can end in a value-creating deal or a distressed one.
What to watch
Any outcome from the strategic review, the pace of draws on the equity line, and cash burn against the non-dilutive licensing capital. The asset has value. Whether shareholders capture it depends on how the capital story resolves.
Disclosure
This article is independent editorial content and reflects the author's opinion and analysis as of the date of publication. It is not investment advice and should not be relied on as the basis for any investment decision. MicroCap Desk and its contributors received no compensation of any kind — cash, securities, or otherwise — from any company mentioned, or from any third party, in connection with this article. The author holds no position in any security mentioned. Information is drawn from sources believed reliable but is not guaranteed accurate or complete. Microcap securities carry a high risk of loss. Do your own research. See our full Disclosure.
